NCT01472848 - A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects | Biotech Hunter

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

August 31, 2011

Conditions

Obesity

Interventions

DRUG

PF 05212389 or placebo

QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.

DRUG

PF 05212389 or placebo

QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.

DRUG

PF 05212389 or placebo

QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts

DRUG

PF 05212389 or placebo

QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts

DRUG

PF 05212389 or placebo

QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts

DRUG

PF 05212389 or placebo

QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts